Clinical Trial Update: INCB018424 in Patients With Advanced Hematologic Malignancies [Phase 2]

View source ↗

Summary

Phase 2 trial of INCB018424 (ruxolitinib) in patients with advanced hematologic malignancies. Results for diseases including AML, ALL, MDS, and CML have been po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Myelodysplastic Syndrome
• Myelogenous Leukemia

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Acute Myeloid Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2020-02-18